Pharmaceuticals, Biotechnology and Life Sciences
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
Roche said on Monday that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) for metastatic urothelial carcinoma (mUC).
Bristol-Myers Squibb (BMS) has reached a payment milestone in connection with the licensing deal with Innate Pharma for lirilumab in combination with Opdivo. BMS has paied Innate $15 million.
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.
Indian drugmaker Natco Pharma has gotten the approval from the U.S. regulator for generic version of Teva’s leukemia treatment Trenda (Bendamustine Hydrochloride powder for Injection).
BMS and Janssen Biotech announced continuation of their work together through a new clinical research.
Celyad has started on Thursday its Therapeutic Immunotherapy with NKR-2 (THINK) trial in Belgium with the first patient giving blood.
To remind, THINK trial is an open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers.
Nicox has provided certain regulatory and clinical updates for NCX 4251, its novel ophthalmic suspension of fluticasone propionate nanocrystals being…